jpad journal

AND option

OR option

Editorial board

Editor-in-Chief

Jacques Touchon (Montpellier, France)
Bruno Vellas (Toulouse, France)
Paul Aisen (San Diego, USA)

Sections and Associate Editors

Methodological Aspects of Preventive Trials: Sandrine Andrieu (Toulouse, France)
Operational Aspects of Preventive Trials: Bruno Vellas (Toulouse, France)
Health Economic and Finances Aspects: Ara Khachaturian (Washington, USA)
Health Policy, Regulations: Zaven Khachaturian (Potomac, USA)
Bioinformatics Analytics: Ron Thomas (San Diego, USA)
Intervention Pharmacological: Paul Aisen (San Diego, USA)
Health Promotion: Mia Kivipelto (Stockholm, Sweden)
Imaging and Biomarkers: Mike Weiner (San Francisco, USA)
Pre-Clinical Study: Natalio Vita (Toulouse, France)
Diabetes and Cognitive Decline: Alan Sinclair (Bedfordshire, United Kingdom)

Editorial Board

R. Amariglio (Brigham and Women’s Hospital, Boston, USA)
K.J. Anstey (The Australian National University, Canberra, Australia)
C. Ballard (University of Exeter, Exeter, United Kingdom)
R. Bateman (Washington University School of Medicine, Saint Louis, USA)
D. Bennett (Rush University Medical Center, Chicago, USA)
K. Blennow (University of Gothenburg, Mölndal, Sweden)
T. Bittner (Genentech/Roche, Basel, Switzerland)
M. Boada (Fundacion ACE, Barcelonna, Spain)
A. Boxer (University of California, San Francisco, USA)
C. Brayne (University of Cambridge, Cambridge, United Kingdom)
J. Breitner (McGill Center for Studies in Aging, Montreal, Canada)
M. Carrillo (Alzheimer’s Association, Chicago, USA)
J.M. Cedarbaum (Biogen Iden, Woodbridge, USA)
P. Chan (Xuanwu Hospital of Capital Medical University, Beijing, China)
S. Craft (Wake Forest Baptist Health, Winston-Salem, USA)
J. Cummings (Cleveland Clinic Lou Ruvo Center for Brain, Las Vegas, USA)
M. Donohue (University of California, San Diego, USA)
R.S. Doody (Baylor College of Medicine, Houston, USA)
B. Dubois (Institut de la Mémoire et de la Maladie d’Alzheimer, Paris, France)
H. Feldman (University of Vancouver, Vancouver, Canada)
L. Feng (National University of Health System, Singapore)
H. Fillit (Alzheimer’s Drug Discovery Foundation , New York, USA)
G. Frisoni (IRCCS San Giovanni Dio, Brescia, Italy)
L. Frölich (University of Heidelberg, Heidelberg, Germany)
M. Geng (Shanghai Green Valley Pharmaceutical Co., Shanghai, China)
J. George (Alzheimer Europe, Luxembourg)
B. Gordon (Washington University, Saint Louis, USA)
J. Grill (University of California, Irvine, USA)
D. Gustafson (State University of New York, New York, USA)
M. Grundman (Global R&D Partners, LLC, San Diego, USA)
H.J. Hampel (Ludwig-Maximilian University, Munich, Germany)
O. Hansson (Lund University, Sweden)
T. Hartmann (Saarland University, Saarland, Germany)
S. Hendrix (Pentara Corporation Salt Lake City, USA)
M. Isaac (European Medicines Agency, London, United Kingdom)
F. Jessen (Rheinische- Friedrich-Wilhelms-Universität, Bonn, Germany)
G. Jicha (UK Healthcare, Lexington, USA)
T. Kwok (The Chinese University of Hong Kong, Shalin, Hong Kong)
J. Langbaum (Banner Alzheimer’s Institute, Phoenix, USA)
Y. Li (Knight Alzheimer Disease Research Center, St. Louis, USA)
Y. Lee (Ajou University School of Medicine, Suwon, Republic of Korea)
V. Legrand (ICON Clinical Research, Nanterre, France)
J.J. Llibre Guerra (Knight Alzheimer Disease Research Center, St. Louis, USA)
J.A. Luchsinger (Columbia University, New York, USA)
G.A. Marshall (Harvard Medical School, Boston, USA)
E. McDade E (Washington University School of Medicine, Saint Louis, USA)
D. Peng (China National Clinical Research Center for Neurological Diseases, Beijing, China)
R. Petersen (Mayo Clinic, Rochester, USA)
Y. Quiroz (Harvard Medical School, Boston, USA)
G. Rabinovici (University of California, San Francisco, USA)
M. Rafii (University of Southern California, San Diego, USA)
R. Raman (University of Southern California, San Diego, USA)
E. Reiman (Banner Alzheimer’s Institute, Phoenix, USA)
E. Richard (University of Amsterdam, Amsterdam, The Netherlands)
C. Ritchie (Imperial College of London, London, United Kingdom)
M. Sabbagh (Lou Ruvo Center for Brain Health, Las Vegas, USA)
S. Salloway (The Warren Alpert Medical School of Brown University, Providence, USA)
C. Scerri (University of Malta, Msida, Malta)
P. Scheltens (Alzheimer Center VUmc, Amsterdam, The Netherlands)
R. Schindler (Pfizer, Inc., New York, USA)
F.A. Schmitt (University of Kentucky, Lexington, USA)
Y. Shen (University of Science and technology of China, Anhui, P.R. China)
J. Shi (Beijing Tiantan Hospital, Beijing, China)
E. Siemers (Lilly Corporate Center, Indianapolis, USA)
A.G. Smith (USF Health Byrd Alzheimer’s Institute, Tampa, USA)
D. Smith (University Department of Pharmacology, Oxford, United Kingdom)
R. Sperling (Brigham and Women’s Hospital, Boston, USA)
P. Tariot (Banner Alzheimer’s Institute, Phoenix, USA)
M. Toma (Universidad Europea, Madrid, Spain)
C. van Dyck (Yale University School of Medicine, New Haven, USA)
S. Villeneuve (McGill University, Montreal, Canada)
P. Wang (University of Yang-Ming, Beijing, China)
P. Whitehouse (Case Western Reserve University, Shaker Heights, USA)
K. Yaffe (University of California, San Francisco, USA)
J.-T. Yu (Qingdao, China)